Equities

SMS Pharmaceuticals Ltd

SMSPHARMA:NSI

SMS Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)368.50
  • Today's Change9.50 / 2.65%
  • Shares traded323.44k
  • 1 Year change+198.50%
  • Beta1.7246
Data delayed at least 15 minutes, as of Sep 20 2024 11:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.

  • Revenue in INR (TTM)7.38bn
  • Net income in INR569.64m
  • Incorporated1987
  • Employees1.20k
  • Location
    SMS Pharmaceuticals LtdPlot No.19-III,OP BHARATIYA VIDYA BHAVANPUBLIC ROAD NO 71, JUBILEE HILLSHYDERABAD 500034IndiaIND
  • Phone+91 4 066288888
  • Fax+91 4 023551401
  • Websitehttps://smspharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sigachi Industries Ltd4.10bn594.65m18.18bn991.0034.00--25.554.431.601.6010.97--------4,136,886.00--14.77--19.5752.3350.3014.4314.92--7.19--1.6132.0825.3431.3424.6470.35--
Hester Biosciences Ltd2.99bn193.56m20.17bn642.00101.92--53.286.7523.2623.26350.03--------4,656,698.00--6.15--7.6971.5266.647.3412.83--2.26--23.2714.4511.33-29.06-14.591.49-11.42
Panacea Biotec Ltd5.46bn-279.53m20.25bn1.15k----266.613.71-4.58-4.5889.84--------4,761,763.00--10.26--16.5360.2450.27-5.2024.87---17.30--0.0021.574.1396.47--74.65--
Syncom Formulations (India) Ltd2.91bn285.50m20.94bn802.0068.35--62.577.200.3260.3262.99--------3,626,019.00--7.50--10.2339.5334.109.829.38--7.67----17.457.1226.1317.95----
Amrutanjan Health Care Ltd4.27bn425.73m22.57bn635.0053.12--46.235.2814.7114.71147.56--------6,726,040.00--16.22--20.1249.6153.099.9713.23--212.51--18.9510.9610.7112.9012.4626.9316.43
Themis Medicare Ltd4.08bn500.16m23.77bn1.54k47.57--38.575.835.435.4344.31--------2,648,322.00--11.12--16.4663.5160.3212.2614.96------7.597.7415.75-23.51--26.73--
IOL Chemicals and Pharmaceuticals Ltd.20.72bn1.19bn28.29bn2.78k23.86--15.301.3720.2020.20353.05--------7,461,253.00--14.91--19.4533.9634.545.7212.00--10.06--10.59-3.804.82-3.39-10.7035.27--
Dishman Carbogen Amcis Ltd24.16bn-2.48bn28.62bn1.13k----165.731.18-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
SMS Pharmaceuticals Ltd7.38bn569.64m30.22bn1.20k52.89--33.964.096.756.7587.48--------6,168,549.00--5.43--7.3330.1233.307.697.87--4.21--6.1735.868.81805.824.478.419.86
Solara Active Pharma Sciences Ltd13.00bn-5.61bn31.68bn2.16k------2.44-143.75-143.75334.17--------6,030,149.00---2.44---3.8437.3441.16-43.17-4.49---1.57-----10.73-1.45-2,458.12---4.81--
Indoco Remedies Ltd18.22bn766.90m34.06bn5.93k44.80--19.561.878.258.25178.33--------3,072,462.00--6.88--9.8568.6165.594.106.93--2.95--14.028.9113.41-30.78--34.5437.97
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn34.42bn1.23k--108.86----------12.72------------------------0.8228--0.2681--43.84--77.37------
RPG Life Sciences Limited6.00bn923.20m34.94bn1.27k37.84--31.635.8355.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Gufic BioSciences Ltd8.14bn863.69m40.16bn1.45k46.04--38.824.938.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Data as of Sep 20 2024. Currency figures normalised to SMS Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

2.55%Per cent of shares held by top holders
HolderShares% Held
quant Money Managers Ltd.as of 30 Aug 20242.15m2.54%
American Century Investment Management, Inc.as of 05 Sep 2024881.000.00%
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 2024412.000.00%
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.